Altaris has agreed to acquire Simulations Plus, a Research Triangle Park-based developer of drug development software, in a $375 million take-private transaction. The private equity firm will pay $18.50 per share to stockholders, valuing the health tech company at roughly $375 million. This represents a significant premium that reflects growing investor appetite for specialized pharmaceutical software platforms.

The deal combines two niche players in computational drug discovery. Altaris plans to merge Simulations Plus with its existing portfolio company Chemical Computing Group, creating a consolidated platform for pharmaceutical modeling and simulation tools. Simulations Plus develops software used in drug development processes, serving pharmaceutical companies and research institutions.

The transaction is expected to close in calendar fourth quarter of 2026, giving both companies time to integrate operations and realize synergies. Take-private transactions have become increasingly common in the health tech sector as private equity firms seek to capitalize on undervalued public companies.

This acquisition strengthens Altaris's position in the specialized drug development software market while providing Simulations Plus shareholders with immediate liquidity at an attractive valuation. The merged entity will likely pursue expanded market share in pharmaceutical modeling tools.